LEADER 02078nas 2200577-a 450 001 996321364603316 005 20240413021858.0 011 $a1027-2852 035 $a(CKB)110975506070987 035 $a(CONSER)sn-92033119- 035 $a(DE-599)ZDB2026878-6 035 $a(EXLCZ)99110975506070987 100 $a19920314a19909999 --- - 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiotecnología aplicada $erevista de la Sociedad Iberolatinoamericana para Investigaciones sobre Interferón y Biotecnología en Salud 210 $aLa Habana, Cuba $cPor el Palacio de las Convenciones para la Sociedad Iberolatinoamericana para Investigaciones sobre Interferón y Biotecnología en Salud$d1990- 215 $a1 online resource 300 $aRefereed/Peer-reviewed 300 $aTitle from cover. 311 08$aPrint version: Biotecnología aplicada : 0864-4551 (DLC)sn 92033119 (OCoLC)25477730 531 $aBIOTECNOL APL 606 $aInterferon$vPeriodicals 606 $aGenetic engineering$vPeriodicals 606 $aRecombinant proteins$vPeriodicals 606 $aGenetic engineering$2fast$3(OCoLC)fst00940027 606 $aInterferon$2fast$3(OCoLC)fst00976239 606 $aRecombinant proteins$2fast$3(OCoLC)fst01091505 606 $aGenetic Engineering 606 $aInterferons 606 $aRecombinant Proteins 608 $aPeriodicals.$2fast 608 $aPeriodical. 615 0$aInterferon 615 0$aGenetic engineering 615 0$aRecombinant proteins 615 7$aGenetic engineering. 615 7$aInterferon. 615 7$aRecombinant proteins. 615 2$aGenetic Engineering. 615 2$aInterferons. 615 2$aRecombinant Proteins. 676 $a616.07905 712 02$aSociedad Iberolatinoamericana para Investigaciones sobre Interferón y Biotecnología en Salud. 906 $aJOURNAL 912 $a996321364603316 920 $aexl_impl conversion 996 $aBiotecnología aplicada$92293192 997 $aUNISA LEADER 03693nam 2200805z- 450 001 9910557615903321 005 20220321 035 $a(CKB)5400000000045243 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79571 035 $a(oapen)doab79571 035 $a(EXLCZ)995400000000045243 100 $a20202203d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aOligonucleotide, Therapy, and Applications 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (123 p.) 311 08$a3-0365-3057-6 311 08$a3-0365-3056-8 330 $aOligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs. 606 $aMedicine$2bicssc 610 $aAmplex Red 610 $aanti-proliferative activity 610 $aantisense oligonucleotide 610 $aantisense oligonucleotides 610 $aantisensense oligonucleotide 610 $aaptamer 610 $aaptasensor 610 $acovalent dimer construct 610 $aDNA methylation 610 $aDNAzyme 610 $adopamine neurotransmission 610 $adouble mutant A30P*A53T* 610 $aexon skipping 610 $afibrillin-1 610 $aFoxp3 610 $aG-quadruplexes 610 $ahistone code 610 $ainfluenza 610 $alight-induced activity 610 $aMarfan syndrome 610 $amicroRNA 610 $amotor deficits 610 $ananoparticles 610 $anoncoding RNA 610 $aParkinson's disease 610 $aprimary cell culture of human glioma 610 $apulmonary arterial hypertension 610 $aquantum dots (QDs) 610 $aregulatory T cells 610 $aROS 610 $aSERS 610 $asplice-switching 610 $aSporothrix schenckii 610 $atransgenic mouse model 610 $avaccine immunogenicity 610 $avirus detection 610 $a?-synuclein 615 7$aMedicine 700 $aAliño$b Salvador$4edt$01303482 702 $aSendra$b Luis$4edt 702 $aAliño$b Salvador$4oth 702 $aSendra$b Luis$4oth 906 $aBOOK 912 $a9910557615903321 996 $aOligonucleotide, Therapy, and Applications$93027103 997 $aUNINA